AstraZeneca Plc's COVID19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters.from Top Business News- News18.com https://ift.tt/2TeUqMl
No comments:
Post a Comment